Clinical Trial Search

Primary: Change of Clostridium Butyricum Miyairi Expression After Probiotics Supplementation in Constipated Children. — 0.00486; 0.0000148; 0.00000189 number of bacteria per mg…

Primary: Progression-Free Survival (PFS) — 22.1; 7.3; 19.0 Weeks — p=0.1315

Primary: Number of Participants With Improvement of Espohageal Eosinophilia — 13; 0 Participants

Primary: Impact of the Comorbidities Profile in Inflammatory Bowel Disease (IBD) Participants on Lack of Treatment Response to Biological Therapy — 0.59; 2.16; 2.67 odds ratio…

Primary: Quality of Recovery Score — 165; 169 score on a scale

Primary: Market Research Survey — 10; 91; 93; 16 Participants

Primary: Number of Participants With Dose-Limiting Toxicities (DLT) — 0; 4 Participants

Primary: Change in Brain Glucose Uptake Measured Using 18F-FDG PET Imaging — -0.06; -0.05 umol/100g/min (change)

Primary: Change in Endogenous Glucose Production (EGP) — 2.45; 2.56; 1.95; 2.4 mg/kg*min

Primary: Percentage of Participants With an Adverse Event (AE) — 68.5; 64.3 Percentage of Participants

Primary: Restoration of Full-length Type VII Collagen as Assessed by Immunofluorescence. — 5; 5; 4; 4 Fluorescence Intensity (MFI) for C7

Primary: Percentage of Participants Who Achieved Remission — 44.0; 22.4 percentage of participants — p=<0.0001

Primary: Clinical Efficacy in the Risk Stratification of Patients With Indeterminate Lesions — 70.37; 46.97; 68.47; 49.21 percentage

Primary: Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale-5 (ADHD-RS-5) Total Score at Week 4 — -9.7; -11.6 Score on a scale — p=0.451

Primary: Change in Insulin Sensitivity From FSIVGTT — 0.20; 0.41; -0.45 10^-5*min^-1*mU^-1*mL